Radiotherapy for Metastatic Melanoma
(CURB-Melanoma Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a special type of radiation treatment called SBRT (Stereotactic Body Radiation Therapy) for individuals with metastatic melanoma, where the cancer has spread to other parts of the body. The goal is to determine if adding this focused radiation to areas of active cancer growth can prevent further progression. Participants will continue their current cancer medication while receiving the radiation treatment. The trial seeks individuals with up to ten active cancer spots outside the brain who are already on first-line treatments like immunotherapy or BRAF inhibitors.
As an unphased trial, this study provides a unique opportunity to explore innovative treatment options that could enhance current therapies.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these radiotherapy techniques are safe for treating metastatic melanoma?
Research shows that Stereotactic Body Radiation Therapy (SBRT) is generally easy for patients to handle. Many studies have found that most people experience only mild side effects. In one study, 49% of patients reported some side effects, but these were mostly mild. Importantly, no serious side effects that would limit treatment emerged. Another study highlighted that SBRT carries a low risk of side effects when treating melanoma patients with cancer spread outside the brain. This suggests that SBRT is a safe option for many people.12345
Why are researchers excited about this trial?
Stereotactic Body Radiation Therapy (SBRT) is unique because it delivers highly focused radiation to metastatic melanoma lesions, minimizing damage to surrounding healthy tissue. Unlike traditional treatments like chemotherapy, which affects the entire body, SBRT targets specific areas, potentially reducing side effects and improving quality of life. Researchers are excited about SBRT's precision and its ability to be combined with existing systemic therapies, offering a promising approach for patients with limited disease progression.
What evidence suggests that this radiotherapy is effective for metastatic melanoma?
Research has shown that stereotactic body radiotherapy (SBRT) effectively treats melanoma when the cancer spreads to a few areas outside the brain. Studies have found that SBRT manages these cases with generally low side effects. In this trial, all participants will receive SBRT alongside their existing first-line systemic therapy. One study found that combining SBRT with other treatments improved outcomes for advanced melanoma. Most patients experienced few side effects, and those that did were mostly mild. This suggests SBRT could help slow the spread of metastasized melanoma.36789
Are You a Good Fit for This Trial?
This trial is for patients with metastatic melanoma who are experiencing limited progression in up to ten extracranial sites, regardless of the total number of metastases. Participants should be suitable for radiotherapy and have measurable disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions while continuing systemic therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Stereotactic Body Radiation Therapy (SBRT)
Trial Overview
The study tests if adding focused radiotherapy (SBRT or hypofractionated) to a few progressing cancer spots can help control metastatic melanoma better and delay overall disease progression.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
This is a single-arm trial, meaning all participants will receive the same treatment. There is no control or comparison group. All eligible patients will continue their existing first-line systemic therapy and receive additional radiation treatment-either stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy-directed at oligoprogressive lesions. The outcomes will be measured and analyzed based on this single group.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Citations
Stereotactic body radiotherapy as a viable treatment on ...
SBRT demonstrated efficacy in managing melanoma patients with extracranial oligometastases and showed an overall low toxicity profile.
Clinical Outcomes and Toxicity using Stereotactic Body ...
In general SBRT was well-tolerated, with 18 patients (49%) reporting toxicity, the majority of which was Grade 1 or 2. Two patients (5%) ...
3.
por-journal.com
por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2022.1610550/fullThe Role of Stereotactic Radiotherapy in the Management ...
In our study we found that systemic therapy combined with stereotactic radiation therapy may improve the efficacy of the treatment in advanced ...
MSB0010445 and Stereotactic Body Radiation Therapy in ...
This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to assess the safety and efficacy of a low dose, ...
A Prospective Study Assessing the Efficacy and Toxicity of ...
Most patients (75.0%; 72/96) had a single metastatic bone site treated with SBRT, and 25.0% (24/96) had 2 to 3 lesions treated (Table 1).
Clinical outcomes of multisite moderate to high dose ...
We analyzed 34 patients with 79 lesions, with a median follow‐up of 17.4 months. Sixty‐eight percent of patients received systemic therapy after the first HDRT.
Clinical Outcomes Among Patients Treated With ...
With median follow-up 19.4 months, 1- and 2-year rates of local control were 94% and 89%, locoregional control was 83% and 67%, progression-free ...
Stereotactic body radiotherapy as a viable treatment on ...
SBRT demonstrated efficacy in managing melanoma patients with extracranial oligometastases and showed an overall low toxicity profile.
Evaluation of Safety of Stereotactic Body Radiotherapy for ...
Standard doses were safe in all 35 evaluable patients, with a median of 3 metastases; there were no protocol-defined dose-limiting toxicities, ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.